Delivery Order SPE2DB24D2216-SPE2DB25FGPMU
- Not listed
- The Defense Logistics Agency awarded a delivery order to AmerisourceBergen Drug Corp for 200-unit vials of Xeomin, a botulinum toxin product used for medical and therapeutic purposes, with a ceiling value of $11,174.80. The contract, awarded on June 26, 2025, with an ultimate completion date of July 18, 2025, is structured as a firm fixed-price delivery order with no set-aside designation. Performance will take place at AmerisourceBergen's corporate office location in Conshohocken, Pennsylvania....
- The Defense Logistics Agency awarded a $6,704.88 delivery order to AmerisourceBergen Drug Corp for 200-unit vials of Xeomin, a botulinum toxin injection used in medical and therapeutic applications. This firm fixed price delivery order, issued on August 7, 2025, represents a competitively awarded, non-set-aside contract with an ultimate completion date of August 28, 2025. The pharmaceutical product will be delivered to AmerisourceBergen's corporate office location in Conshohocken,...
- The Defense Logistics Agency awarded AmerisourceBergen Drug Corp a $2,793.70 delivery order for Xeomin 100 Unit Vials, a botulinum toxin product used for medical purposes. This competitive award, issued on August 25, 2025, carries an ultimate completion date of September 16, 2025, and utilizes firm fixed pricing with no set-aside designation. Performance will take place at AmerisourceBergen's corporate office in Conshohocken, Pennsylvania. The delivery order is issued under the company's...
- The Defense Logistics Agency awarded a delivery order to AmerisourceBergen Drug Corp for 200-unit vials of Xeomin, a botulinum toxin product commonly used for therapeutic and cosmetic applications in military and veteran healthcare settings. This firm fixed-price delivery order, valued at $2,514.33, was competitively awarded without set-aside provisions and is scheduled for completion by September 17, 2025. AmerisourceBergen, headquartered in Conshohocken, Pennsylvania, serves as the performance...
- The Defense Logistics Agency awarded a $14.4K delivery order to AmerisourceBergen Drug Corp for 200-unit vials of Xeomin, a botulinum toxin product used in medical and therapeutic applications. This firm fixed price delivery order was competitively awarded without set-aside designation and is scheduled for completion by October 7, 2025. The work will be performed at AmerisourceBergen's corporate office location in Conshohocken, Pennsylvania. This delivery order is issued under...
- The Defense Logistics Agency awarded a $1,215.76 firm fixed-price delivery order to AmerisourceBergen Drug Corp for 50-unit vials of Xeomin, a botulinum toxin product used for medical and therapeutic purposes. This non-set-aside contract was competitively awarded with an ultimate completion date of August 28, 2025, and represents a delivery order under AmerisourceBergen's larger Indefinite Delivery Contract with DLA Troop Support Medical (SPE2DX), valued at $999,999,999.00 through December 2026....
- The Defense Logistics Agency awarded a delivery order valued at $8,381.10 to AmerisourceBergen Drug Corp for 100-unit vials of Xeomin, a botulinum toxin-based therapeutic product used for medical applications. This non-set-aside, competitively awarded contract is issued under a firm fixed price structure with an ultimate completion date of September 19, 2025. The order will be fulfilled from AmerisourceBergen's Conshohocken, Pennsylvania facility, where the company maintains its corporate...
- The Defense Logistics Agency awarded a $1,396.85 delivery order to AmerisourceBergen Drug Corp for 100-unit vials of Xeomin, a botulinum toxin product used for therapeutic and cosmetic medical applications. This firm fixed price delivery order, issued on July 24, 2025, with an ultimate completion date of August 14, 2025, will be performed at the contractor's Corporate Office location in Conshohocken, Pennsylvania. The award was made through open competition with no set-aside designation. This...
- The Defense Logistics Agency awarded a $27,937 firm fixed-price delivery order to AmerisourceBergen Drug Corp for 100-unit vials of Xeomin, a botulinum toxin product used for medical and therapeutic purposes. The contract, issued on September 18, 2025, with an ultimate completion date of October 9, 2025, represents a non-competitive, direct fulfillment order under AmerisourceBergen's existing Indefinite Delivery Contract vehicle. The place of performance is AmerisourceBergen's corporate office...
- The Defense Logistics Agency awarded a delivery order valued at $2,234.96 to AmerisourceBergen Drug Corp for 100-unit vials of Xeomin, a botulinum toxin product used in medical and therapeutic applications. This firm fixed-price delivery order, issued on September 5, 2025, with completion targeted for September 26, 2025, is being fulfilled from the vendor's location in Conshohocken, Pennsylvania. The award utilizes no set-aside designation, indicating it was competitively awarded under open...
- SPE2DB24D2216Indefinite Delivery Contract
- SPE2DB24D2216-SPE2DB25FGPMUDelivery Order
The Defense Logistics Agency awarded a delivery order valued at $2,793.70 to AmerisourceBergen Drug Corp for 100-unit vials of Xeomin, a botulinum toxin product used for medical and therapeutic purposes. The contract, awarded on August 12, 2025, with an ultimate completion date of September 3, 2025, represents a firm fixed-price delivery order with no set-aside designation. Performance will occur at AmerisourceBergen's corporate office location in Conshohocken, Pennsylvania. This delivery order is issued under AmerisourceBergen's larger Indefinite Delivery Contract (IDC) with DLA Troop Support Medical, a $999.999 billion comprehensive pharmaceutical supply vehicle running through December 2026. AmerisourceBergen Drug Corp, a major pharmaceutical distributor and critical federal medical procurement vendor, regularly fulfills delivery orders for specialized pharmaceutical products supporting military and veteran healthcare systems. The company's IDC with the Defense Logistics Agency enables it to supply a broad range of pharmaceutical commodities, including specialty medications, vaccines, and medical supplies across multiple therapeutic domains to support Defense Health Agency operations and other government healthcare systems globally. This particular delivery order for Xeomin reflects the ongoing pharmaceutical supply needs within the federal medical supply chain managed through DLA's established prime vendor relationships.
Mod # | Description | ReasonForModification | Federal Obligation | Date |
|---|---|---|---|---|
| Not listed | Not listed | $2.8k | 8/12/25 |